ABLE Financial Group LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

ABLE Financial Group LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,534 shares of the biopharmaceutical company's stock, valued at approximately $234,000.

A number of other institutional investors and hedge funds have also modified their holdings of GILD. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $33,000. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Thursday, February 13th. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Finally, Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $110.55.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,929 shares of company stock worth $5,644,780. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Down 0.7%

Gilead Sciences stock traded down $0.76 during trading hours on Friday, reaching $110.35. 11,912,493 shares of the company's stock traded hands, compared to its average volume of 7,739,767. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm's 50 day moving average is $105.45 and its 200-day moving average is $100.67. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market capitalization of $137.27 billion, a price-to-earnings ratio of 298.24, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm earned ($1.32) earnings per share. The business's revenue for the quarter was down .3% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.